Kristin Patrick Increases Stake in Niagen Bioscience
Kristin Patrick acquired 31,746 shares of Niagen Bioscience on June 24, 2026.
Key Points
- Kristin Patrick purchased 31,746 shares of Niagen Bioscience, Inc. on June 24, 2026, as part of an insider transaction.
- Shares of Niagen Bioscience traded near $3.42 on Saturday, with a market cap of approximately $272.4 million and a P/E ratio of 16.3.
- Analysts from HC Wainwright & Co. and Canaccord Genuity maintain a 'buy' rating with price targets ranging from $10 to $23.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Kristin Patrick, an insider at Niagen Bioscience, Inc. (NasdaqCM: NAGE), recently purchased 31,746 shares of the company. The transaction took place on June 24, 2026. This move adds to the overall insider activity at the company.
Other Institutional Activity in Niagen Bioscience
BlackRock, Inc. reduced its holdings by 204,090 shares, leaving it with 3,871,619 shares valued at roughly $17.1 million. SteelPeak Wealth, LLC opened a new position with 3,373,000 shares, worth about $14.9 million. Arrowstreet Capital, Limited Partnership increased its stake by 761,685 shares, ending with 2,378,437 shares valued at approximately $10.5 million, marking a 47.1% increase. Vanguard Capital Management LLC also opened a new position with 2,149,277 shares, valued at around $9.5 million. Meanwhile, Tieton Capital Management, LLC boosted its holdings by 384,062 shares, totaling 2,029,155 shares worth about $8.9 million, a 23.3% increase.
Niagen Bioscience, Inc. Stock Up 4.0%
Shares of Niagen Bioscience, Inc. traded near $3.42 on Saturday. The company has a market capitalization of about $272.4 million, with a P/E ratio of 16.3 and a forward P/E of 10.7. Its beta stands at 2.06. The stock has seen a 52-week low of $3.29 and a high of $14.69, with its 50-day moving average at $3.99 and the 200-day moving average at $5.83. The company has a strong current ratio of 4.61 and a quick ratio of 3.48, but a relatively high debt-to-equity ratio of 3.13.
$NAGE stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Niagen Bioscience reported revenue of $130.4 million, showing a modest growth of 3.3%. The company achieved a net margin of 14.3% and a return on equity of 27.1%. Its earnings per share were $0.21. The next earnings report is expected on August 5, 2026.
Insider Buying and Selling at Niagen Bioscience, Inc.
On June 24, 2026, several insiders, including Jaksch Frank Jr, Ng Wang Yu Gary, Ann Cohen, Kristin Patrick, Steven Rubin, and Hamed Shahbazi, each purchased 31,746 shares of Niagen Bioscience. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On May 11, 2026, HC Wainwright & Co. maintained their 'buy' rating for Niagen Bioscience with a price target of $11. Canaccord Genuity also maintained their 'buy' rating on May 5, 2026, setting a target of $10. The consensus among analysts is a 'buy' rating with a mean target price of $12.6, based on five analyst opinions.
About Niagen Bioscience
Headquartered in Los Angeles, California, Niagen Bioscience, Inc. operates in the healthcare sector, specifically within biotechnology. The company focuses on developing products that support healthy aging. It offers dietary supplements containing its proprietary ingredients, such as nicotinamide adenine dinucleotide (NAD+), which plays a crucial role in cellular metabolism. Niagen Bioscience sells these products directly to consumers and through various distribution channels, including e-commerce platforms like Amazon. The company, previously known as ChromaDex Corporation, underwent a name change in March 2025 and employs 117 people under the leadership of CEO Robert N. Fried.
Bottom Line
Kristin Patrick's recent purchase of Niagen Bioscience shares highlights ongoing interest in the company's stock among insiders. Niagen Bioscience is known for its innovative approach in the biotechnology sector, focusing on products that promote healthy aging. Analysts maintain a positive outlook, with several firms holding 'buy' ratings and setting varied price targets. As always, it's important to remember that insider transactions are disclosed after the fact and reflect personal investment decisions.
Get Niagen Bioscience, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NAGE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.